2021
DOI: 10.1016/j.msard.2021.102793
|View full text |Cite
|
Sign up to set email alerts
|

The presence of SARS-CoV2 antibodies in MS patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
9
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 11 publications
2
9
0
Order By: Relevance
“…Our data suggest a clear reduction of anti-TSP IgG titers in pwMS treated with anti-CD20 DMT compared with HS. These results are in agreement with previous data showing a weakened humoral response to (i) vaccines administered in pwMS treated with OCR as well as in patients treated with RTX for immune thrombocytopenia [ 3 , 8 ] and (ii) COVID-19 infection in pwMS treated with OCR [ 9 , 10 ].…”
Section: Discussionsupporting
confidence: 93%
“…Our data suggest a clear reduction of anti-TSP IgG titers in pwMS treated with anti-CD20 DMT compared with HS. These results are in agreement with previous data showing a weakened humoral response to (i) vaccines administered in pwMS treated with OCR as well as in patients treated with RTX for immune thrombocytopenia [ 3 , 8 ] and (ii) COVID-19 infection in pwMS treated with OCR [ 9 , 10 ].…”
Section: Discussionsupporting
confidence: 93%
“…In summary, we here demonstrate that pwMS on anti-CD20 treatment develop an immunological SARS-CoV-2 T cell memory response that displays similar characteristics as pwMS on other DMTs and HC, while the humoral response is affected by treatment including a tendency of decreasing antibody levels but with a remaining strong T cell response (Ibarrondo et al, 2020;Maillart et al, 2020;Peng et al, 2020;Wallach and Picone, 2021;Weiskopf et al, 2020). Furthermore, the post-vaccination data are in accordance with ll OPEN ACCESS iScience Article previous studies reporting an attenuated antibody response to SARS-CoV-2 mRNA and also other types of vaccines for patients on anti-CD20 treatment (Achiron et al, 2021;Baker et al, 2020;Bar-Or et al, 2020;Bigaut et al, 2021;Gallo et al, 2021;Guerrieri et al, 2021) and also demonstrate that absence of B cells in blood is a poor predictor of capacity to develop a humoral response.…”
Section: Discussionmentioning
confidence: 54%
“…These results are consistent with previous case reports or case series, which suggest an absence or a poor humoral response after COVID-19 in patients with anti-CD20 mAb. [6][7][8][9] Indeed, depleting B cells from pre-B cells to mature B cells, ocrelizumab affects humoral responses to infection and, subsequently, antibody production. 3 A case series on DMTs in SARS-CoV-2 antibody-positive patients with MS showed that among the 14 patients, 6 patients were treated with fingolimod, suggesting a humoral response.…”
Section: Discussionmentioning
confidence: 99%